Latest / Let's Talk Risk! Podcast / Deep Dive: First FDA Warning Letter Under QMSR

Transcript

Deep Dive: First FDA Warning Letter Under QMSR · Let's Talk Risk! Podcast

• 0:00
  SPEAKER_01: Imagine for a second that you manufacture foot pedals that control surgical lasers.
• 0:05
  SPEAKER_00: And we aren't talking about laser pointers here.
• 0:07
  SPEAKER_00: These are class four medical lasers.
• 0:09
  SPEAKER_01: Right, exactly.
• 0:10
  SPEAKER_01: Devices that are so powerful that,
• 0:12
  SPEAKER_01: you know,
• 0:12
  SPEAKER_01: an accidental activation could instantly cause severe collateral tissue damage
• 0:17
  SPEAKER_01: or burns or even blindness.
• 0:19
  SPEAKER_00: It's incredibly high stakes.
• 0:20
  SPEAKER_01: Very high stakes.
• 0:21
  SPEAKER_01: So a customer reaches out to you and tells you that six of your pedals just failed
• 0:25
  SPEAKER_01: a calibration verification test at their facility.
• 0:28
  SPEAKER_00: Hmm.
• 0:28
  SPEAKER_01: You open an official corrective action form and under the field labeled root cause,
• 0:33
  SPEAKER_01: you simply write nothing.
• 0:35
  SPEAKER_01: You leave it completely blank.
• 0:36
  SPEAKER_00: Just totally blank.
• 0:37
  SPEAKER_01: Yeah.
• 0:38
  SPEAKER_01: And I mean,
• 0:39
  SPEAKER_01: a few months ago,
• 0:40
  SPEAKER_01: the FDA might have dug through your design files to figure out how this happened.
• 0:44
  SPEAKER_01: But as of February 2, 2026,
• 0:46
  SPEAKER_01: that literal blank space just triggered a historic first of its kind warning letter.
• 0:52
  SPEAKER_00: Oh, yeah, it really did.
• 0:53
  SPEAKER_01: So welcome to today's Deep Dive.
• 0:55
  SPEAKER_01: We are speaking directly to you,
• 0:57
  SPEAKER_01: the senior quality assurance and regulatory affairs professionals,
• 1:00
  SPEAKER_01: the ones who actually have to translate all this dense regulatory text
• 1:03
  SPEAKER_01: into real functioning systems on the manufacturing floor.
• 1:07
  SPEAKER_00: Because honestly, the landscape you operate in just experienced a tectonic shift.
• 1:12
  SPEAKER_00: I mean, we are now living in the era of the quality management system regulation or the QMSR.
• 1:18
  SPEAKER_01: Okay, let's unpack this.
• 1:19
  SPEAKER_01: The FDA just completely rewrote the rules for medical device manufacturing,
• 1:24
  SPEAKER_01: replacing the classic 21 CFR Part 820 that the industry has relied on for decades.
• 1:29
  SPEAKER_00: Right, the old QSR.
• 1:31
  SPEAKER_01: Exactly.
• 1:31
  SPEAKER_01: So today,
• 1:32
  SPEAKER_01: we're going to look at the very first company to get caught
• 1:34
  SPEAKER_01: in this new regulatory net,
• 1:36
  SPEAKER_01: and we are going to use their mistakes to figure out exactly how
• 1:39
  SPEAKER_01: the FDA's new auditing algorithm actually works.
• 1:42
  SPEAKER_00: It's a perfect case study.
• 1:43
  SPEAKER_01: It really is.
• 1:44
  SPEAKER_01: To do that,
• 1:45
  SPEAKER_01: we have to look at the warning letter issued to Linemaster Switch Corporation
• 1:48
  SPEAKER_01: in May 2026.
• 1:50
  SPEAKER_01: But, you know,
• 1:51
  SPEAKER_01: before we get to their specific failures,
• 1:53
  SPEAKER_01: we need to understand the new trap itself,
• 1:55
  SPEAKER_01: like what structurally happened on February 2nd.
• 1:57
  SPEAKER_00: Well, structurally,
• 1:59
  SPEAKER_00: the FDA basically aligned its regulations with the International Consensus Standard,
• 2:04
  SPEAKER_00: which is ISO 13485.2016.
• 2:07
  SPEAKER_00: Okay.
• 2:09
  SPEAKER_00: For decades, the FDA operated on its own distinct subpar
• 2:15
  SPEAKER_00: So very compartmentalized.
• 2:23
  SPEAKER_00: Completely.
• 2:25
  SPEAKER_00: And I mean the foundational expectation that you will build a safe
• 2:28
  SPEAKER_00: and effective medical device hasn't changed.
• 2:30
  SPEAKER_00: But the syntax is entirely different now.
• 2:32
  SPEAKER_00: The clause structures have shifted.
• 2:34
  SPEAKER_00: And most importantly,
• 2:36
  SPEAKER_00: the psychological lens through which
• 2:37
  SPEAKER_00: an FDA auditor views your corporate data is fundamentally different.
• 2:41
  SPEAKER_01: I was trying to visualize this earlier,
• 2:43
  SPEAKER_01: and it feels like a total change in inspection philosophy.
• 2:46
  SPEAKER_00: Yeah.
• 2:46
  SPEAKER_01: Like under the old rules,
• 2:47
  SPEAKER_01: the FDA audited you like a health inspector looking at individual ingredients in
• 2:51
  SPEAKER_01: a restaurant's pantry.
• 2:52
  SPEAKER_01: OK, I like that.
• 2:53
  SPEAKER_01: They'd check the flour, you know, check the eggs.
• 2:56
  SPEAKER_01: And if each ingredient looked OK in isolation, you passed.
• 2:59
  SPEAKER_01: But now under QMSR, it's like they're auditing the recipe itself.
• 3:03
  SPEAKER_01: They're following the ingredients from the fridge to the prep station to the pan to
• 3:06
  SPEAKER_01: the plate just to see exactly where the contamination happens.
• 3:09
  SPEAKER_00: That is the perfect mechanism to describe it, honestly.
• 3:13
  SPEAKER_00: Because under the new QMSR, the FDA auditor is evaluating the system holistically.
• 3:19
  SPEAKER_00: Under the old QSR,
• 3:20
  SPEAKER_00: it was incredibly easy for a company to just treat regulatory requirements
• 3:25
  SPEAKER_00: as disconnected checkboxes.
• 3:26
  SPEAKER_01: Right, like risk management lived in the engineering department.
• 3:29
  SPEAKER_00: Exactly.
• 3:29
  SPEAKER_00: Rework lived in the manufacturing department.
• 3:31
  SPEAKER_00: Customer complaints lived in post-market surveillance.
• 3:33
  SPEAKER_01: Total silos.
• 3:34
  SPEAKER_00: Total silos.
• 3:35
  SPEAKER_00: Under QMSR,
• 3:36
  SPEAKER_00: the FDA expects to see a continuous,
• 3:39
  SPEAKER_00: unbroken thread running across the entire product lifecycle.
• 3:43
  SPEAKER_00: If one department drops the thread, the whole system unravels.
• 3:46
  SPEAKER_01: And to see exactly how fast that unraveling happens in the real world,
• 3:50
  SPEAKER_01: we turn to Linemaster Switch Corporation.
• 3:52
  SPEAKER_01: As I mentioned in the beginning,
• 3:53
  SPEAKER_01: they manufacture foot pedal accessories for medical devices,
• 3:57
  SPEAKER_01: and they just received the landmark warning letter,
• 3:59
  SPEAKER_01: the very first one under the new QMSR regime.
• 4:02
  SPEAKER_00: Yeah,
• 4:02
  SPEAKER_00: and the FDA auditor walked into their facility and immediately identified a break in
• 4:07
  SPEAKER_00: that thread we were talking about.
• 4:08
  SPEAKER_01: Right out of the gate.
• 4:09
  SPEAKER_00: Right out of the gate.
• 4:10
  SPEAKER_00: The very first citation falls under ISO 13485.2016,
• 4:16
  SPEAKER_00: Clause 7.1, which governs product realization.
• 4:19
  SPEAKER_01: Okay.
• 4:19
  SPEAKER_00: The FDA cited line master because they failed to have a process FMEA,
• 4:23
  SPEAKER_00: a failure mode,
• 4:24
  SPEAKER_00: and effects analysis for a specific laser foot pedal on their manufacturing floor.
• 4:29
  SPEAKER_01: Wait, I need to stop you there and push back a little.
• 4:31
  SPEAKER_01: A missing process FMEA sounds like a paperwork error, like just a misdocument in a binder.
• 4:37
  SPEAKER_01: Why is the FDA treating a missing piece of paper like
• 4:40
  SPEAKER_01: a critical safety hazard right out of the gate in this new era?
• 4:43
  SPEAKER_00: Because of what that piece of paper represents functionally.
• 4:46
  SPEAKER_00: It is not just documentation, you know.
• 4:49
  SPEAKER_00: It is the blueprint for how you predict and prevent failure during assembly.
• 4:52
  SPEAKER_01: Oh, I see.
• 4:53
  SPEAKER_00: And this perfectly encapsulates the shift to the QMSR.
• 4:56
  SPEAKER_00: Under the old QSR, risk management was heavily associated with design controls.
• 5:00
  SPEAKER_00: Engineers would build a risk file during development,
• 5:04
  SPEAKER_00: pat themselves on the back and put it on a shelf.
• 5:06
  SPEAKER_01: Job done.
• 5:06
  SPEAKER_00: It's exactly job done.
• 5:08
  SPEAKER_00: But Clause 7.1 is about product realization, the actual physical manufacturing processes.
• 5:14
  SPEAKER_01: So the FDA is saying that risk isn't a theoretical exercise anymore.
• 5:18
  SPEAKER_01: It has to actually govern what the operators are doing on, like, Tuesday morning.
• 5:22
  SPEAKER_00: Precisely.
• 5:23
  SPEAKER_00: If you don't have a process FMEA evaluating the risks on your assembly line,
• 5:28
  SPEAKER_00: you're flying blind.
• 5:29
  SPEAKER_00: You don't know what happens if a machine calibrates a millimeter too far to the left
• 5:33
  SPEAKER_00: or, you know, if an operator uses the wrong adhesive.
• 5:36
  SPEAKER_00: Right.
• 5:36
  SPEAKER_00: You are in direct violation of Clause 7.1 because you have an integrated risk
• 5:41
  SPEAKER_00: into your daily operations.
• 5:42
  SPEAKER_01: And line master immediately proved why flying blind on the floor is so dangerous.
• 5:47
  SPEAKER_01: Let's look at what actually happened during assembly.
• 5:49
  SPEAKER_01: This brings us to their citation under Clause 8.3.4, which covers rework.
• 5:54
  SPEAKER_00: Yeah, this one is wild.
• 5:55
  SPEAKER_01: It is.
• 5:55
  SPEAKER_01: Linemester had a specific production run where
• 5:57
  SPEAKER_01: an assembler was reworking foot pedals because they had just failed
• 6:00
  SPEAKER_01: a calibration test.
• 6:02
  SPEAKER_01: And what did the assembler do?
• 6:03
  SPEAKER_01: Nothing good.
• 6:04
  SPEAKER_01: Seriously.
• 6:05
  SPEAKER_01: They failed to apply the proper torque.
• 6:07
  SPEAKER_01: They failed to recalibrate the units after tweaking them.
• 6:09
  SPEAKER_01: And absolutely none of this rework was documented.
• 6:12
  SPEAKER_00: Which is terrifying when we go back to the clinical application.
• 6:15
  SPEAKER_00: These pedals control surgical lasers.
• 6:17
  SPEAKER_01: Right.
• 6:18
  SPEAKER_00: Let's think about the mechanics of that.
• 6:19
  SPEAKER_00: If an assembly doesn't apply the specified torque to internal components,
• 6:23
  SPEAKER_00: the mechanical resistance of that pedal changes.
• 6:26
  SPEAKER_00: A surgeon relies on muscle memory and foot pressure to deliver an exact wattage
• 6:32
  SPEAKER_00: of laser energy to a patient's tissue.
• 6:35
  SPEAKER_01: Wow, okay.
• 6:36
  SPEAKER_01: So inadequate calibration could lead to unintended laser activation.
• 6:39
  SPEAKER_00: Or a massive spike in power delivery.
• 6:42
  SPEAKER_00: The FDA cited them under Clause 8.3.4 because they failed to perform rework
• 6:47
  SPEAKER_00: in accordance with documented procedures that actually evaluate the adverse effects
• 6:51
  SPEAKER_00: of that rework on the final product.
• 6:53
  SPEAKER_01: So they have an undocumented risky rework process happening on the floor.
• 6:56
  SPEAKER_01: But what happens when that flawed device actually makes it out the door and into a hospital?
• 7:01
  SPEAKER_01: How did their system handle the inevitable blowback?
• 7:04
  SPEAKER_00: Well, poorly.
• 7:04
  SPEAKER_01: Yeah, that's what leads to the CPA citation.
• 7:07
  SPEAKER_01: And this is the one that honestly made my jaw drop.
• 7:09
  SPEAKER_01: Clause 8.5.2, Corrective Action.
• 7:12
  SPEAKER_00: This is where we see the blank space.
• 7:14
  SPEAKER_01: Right.
• 7:14
  SPEAKER_01: Linemaster received a SCAR, a supplier or customer request for corrective action.
• 7:19
  SPEAKER_01: A customer explicitly told them that six foot pedals failed
• 7:22
  SPEAKER_01: a calibration verification test on site.
• 7:26
  SPEAKER_01: The FDA auditor pulls this official corrective action record and
• 7:29
  SPEAKER_01: the root cause field is literally left blank.
• 7:33
  SPEAKER_01: Just blank.
• 7:34
  SPEAKER_01: And the corrective action field is marked N-A.
• 7:36
  SPEAKER_00: It just demonstrates the total collapse of the quality system's feedback loop.
• 7:41
  SPEAKER_00: I mean, a customer hands you a critical failure on a silver platter,
• 7:44
  SPEAKER_00: and your official corporate record essentially shrugs its shoulders.
• 7:48
  SPEAKER_00: Clause 8.5.2 demands a rigorous investigation into the cause of nonconformities
• 7:52
  SPEAKER_00: to prevent their recurrence.
• 7:54
  SPEAKER_00: By leaving the root cause blank,
• 7:56
  SPEAKER_00: Linemaster proved they had no mechanism to investigate their own failures.
• 7:59
  SPEAKER_01: But wait,
• 8:00
  SPEAKER_01: doesn't an electronic quality management system usually require those fields
• 8:03
  SPEAKER_01: to be filled out before you can close a ticket?
• 8:06
  SPEAKER_00: Usually, yes.
• 8:07
  SPEAKER_00: Which means either their software allowed them to bypass mandatory fields
• 8:11
  SPEAKER_00: or they were using paper systems that nobody reviewed.
• 8:14
  SPEAKER_01: Wow.
• 8:15
  SPEAKER_00: Either way, the FDA isn't just looking at the blank space.
• 8:18
  SPEAKER_00: They're looking at a management team that signed off on a blank space.
• 8:22
  SPEAKER_01: Here's where it gets really interesting because the auditor didn't stop at the paperwork.
• 8:26
  SPEAKER_01: They tied the calibration failures directly to the physical room the devices were built in.
• 8:31
  SPEAKER_00: Right, the environment.
• 8:32
  SPEAKER_01: They cited Linemaster under clause 6.4.1 for work environment and clause 7.6
• 8:38
  SPEAKER_01: for software validation.
• 8:39
  SPEAKER_00: What's fascinating here is how
• 8:41
  SPEAKER_00: the ISO structure explicitly forces these disparate concepts together.
• 8:47
  SPEAKER_00: The FDA discovered that Linemaster had a known issue where temperature fluctuations
• 8:51
  SPEAKER_00: in their facility caused a sensor's output to drift.
• 8:54
  SPEAKER_00: And this drift led to measurement inaccuracies over time.
• 8:57
  SPEAKER_00: Yet, they had no controls in place to monitor the ambient temperature
• 9:01
  SPEAKER_00: of their work environment to ensure
• 9:02
  SPEAKER_00: that their calibration equipment remained accurate.
• 9:05
  SPEAKER_01: And the only control they did try to implement was a total disaster.
• 9:09
  SPEAKER_01: They had some monitor program software labeled TM118 that was supposed to track things.
• 9:14
  SPEAKER_00: Supposed to, yeah.
• 9:15
  SPEAKER_01: But during validation,
• 9:16
  SPEAKER_01: that software lacked raw data,
• 9:18
  SPEAKER_01: it lacked statistical analysis, and it didn't even have pass-fail criteria.
• 9:23
  SPEAKER_01: They didn't even verify that the software accurately measured
• 9:26
  SPEAKER_01: the output values it was supposed to be monitoring.
• 9:29
  SPEAKER_00: So you have a work environment where the temperature actively ruins the calibration
• 9:33
  SPEAKER_00: of surgical equipment,
• 9:34
  SPEAKER_00: and the only safeguard is an unvalidated piece of software pretending to keep an eye
• 9:39
  SPEAKER_00: on it.
• 9:39
  SPEAKER_01: Just a perfect storm.
• 9:40
  SPEAKER_00: Exactly.
• 9:41
  SPEAKER_00: Under the QMSR,
• 9:42
  SPEAKER_00: the FDA leverages Clause 6.4.1 to point out that
• 9:46
  SPEAKER_00: when environmental conditions can have an adverse effect on product quality,
• 9:50
  SPEAKER_00: you must document and monitor that environment.
• 9:53
  SPEAKER_00: It brings environmental controls,
• 9:55
  SPEAKER_00: calibration, and software validation into a very tight logical relationship.
• 9:59
  SPEAKER_01: So that is the Linemaster Warning Letter, the QMSR in action.
• 10:04
  SPEAKER_01: It's holistic, it's interconnected, and it leaves nowhere to hide.
• 10:08
  SPEAKER_01: But, you know,
• 10:08
  SPEAKER_01: to truly grasp the magnitude of what the FDA is doing here,
• 10:11
  SPEAKER_01: we have to look backward.
• 10:13
  SPEAKER_01: To understand this new trap,
• 10:14
  SPEAKER_01: we need to see how the FDA behaved under the old rules just months prior.
• 10:18
  SPEAKER_00: Exactly.
• 10:19
  SPEAKER_00: Holding the old enforcement paradigm up against the new one makes the shift in
• 10:23
  SPEAKER_00: the FDA's expectations incredibly clear.
• 10:26
  SPEAKER_01: Let's start with risk management.
• 10:28
  SPEAKER_01: The siloed approach versus the lifecycle approach.
• 10:31
  SPEAKER_01: We just saw Linemaster get hit under clause 7.1 for lacking a process FMEA on
• 10:35
  SPEAKER_01: the manufacturing floor.
• 10:36
  SPEAKER_01: Right.
• 10:38
  SPEAKER_01: Contrast that with Envoy Medical.
• 10:40
  SPEAKER_01: They received a late QSR era warning letter in November 2025
• 10:45
  SPEAKER_01: for their esteemed second implantable hearing system.
• 10:48
  SPEAKER_00: Yeah, and Envoy was cited under the classic QSR citation for risk,
• 10:52
  SPEAKER_00: which is 21 CFR 820.30 design validations.
• 10:57
  SPEAKER_00: Under the QSR, Risk was almost entirely trapped in the design file.
• 11:00
  SPEAKER_00: It was an engineering exercise.
• 11:02
  SPEAKER_01: And Envoy's engineering exercise was incredibly siloed.
• 11:04
  SPEAKER_01: Let's look at the mechanics of what they did.
• 11:06
  SPEAKER_01: They were evaluating three different contamination sources in their manufacturing process.
• 11:11
  SPEAKER_01: One was an issue with filtered air.
• 11:12
  SPEAKER_01: One was a contaminated water system.
• 11:14
  SPEAKER_01: And one was physical contamination left on an assembly.
• 11:17
  SPEAKER_01: Now, all three of these hazards lead to the exact same clinical outcome for the patient.
• 11:22
  SPEAKER_01: Which is a severe infection from a sterile implantable device.
• 11:27
  SPEAKER_01: But Envoy assigned them completely different severity ratings in their risk analysis.
• 11:31
  SPEAKER_00: It's just wild.
• 11:32
  SPEAKER_00: They rated the air and water contamination as a severity level,
• 11:36
  SPEAKER_00: indicating, quote, temporary health problems requiring routine medical care.
• 11:41
  SPEAKER_00: But the assembly contamination was rated as a severity level,
• 11:44
  SPEAKER_00: indicating life-threatening consequences.
• 11:47
  SPEAKER_01: For the exact same patient outcome, I mean,
• 11:49
  SPEAKER_01: an infection in the skull from an implant is an infection that Regardless of
• 11:53
  SPEAKER_01: whether it came from the air or a dirty workstation.
• 11:56
  SPEAKER_01: And to make matters worse, they completely missed endotoxin risks on their finished device.
• 12:00
  SPEAKER_00: Yeah.
• 12:01
  SPEAKER_00: And let's explain why missing endotoxins is such a critical failure.
• 12:05
  SPEAKER_00: Endotoxins are not live bacteria.
• 12:07
  SPEAKER_00: They are the structural components, the toxic outer membranes of dead gram-negative bacteria.
• 12:12
  SPEAKER_00: If you use contaminated water during manufacturing and then you sterilize
• 12:16
  SPEAKER_00: the final device, the live bacteria die.
• 12:19
  SPEAKER_01: But the fragments are still there.
• 12:20
  SPEAKER_00: Exactly.
• 12:20
  SPEAKER_00: The endotoxin fragments remain on the implant.
• 12:23
  SPEAKER_00: When that implant goes into a patient,
• 12:25
  SPEAKER_00: those fragments trigger a massive, sometimes fatal immune response.
• 12:29
  SPEAKER_01: Oh, wow.
• 12:30
  SPEAKER_00: Envoy only tested their water system for live bioburden and assumed that was good enough.
• 12:35
  SPEAKER_00: They entirely missed the endotoxin hazard on the finished product.
• 12:38
  SPEAKER_01: So Envoy got cited under design validation
• 12:41
  SPEAKER_01: because their hazard analysis document was inconsistent.
• 12:44
  SPEAKER_01: But Linemaster got cited under product realization because they lacked
• 12:48
  SPEAKER_01: a risk process on the floor.
• 12:50
  SPEAKER_00: This raises an important question for QARA leaders right now.
• 12:53
  SPEAKER_00: Where does your risk live?
• 12:55
  SPEAKER_00: The FDA is signaling that under QMSR,
• 12:57
  SPEAKER_00: you can't just point to a design document from five years ago and say,
• 13:00
  SPEAKER_00: well, we did risk.
• 13:01
  SPEAKER_01: Yeah, check the box.
• 13:02
  SPEAKER_00: Doesn't work anymore.
• 13:03
  SPEAKER_00: Risk is a living, breathing, life cycle requirement that must span all operations.
• 13:08
  SPEAKER_01: Let's move to our next comparison, KPA and complaint handling, blanks versus blind spots.
• 13:13
  SPEAKER_01: We talked about Linemaster leaving the root cause field literally blank under QMSR clause 8.5.2.
• 13:20
  SPEAKER_01: But let's look at Zoell Medical's warning letter from April 2026,
• 13:25
  SPEAKER_01: cited under the old QSR 820.100A for AKP procedures.
• 13:31
  SPEAKER_01: This wasn't a blank form.
• 13:32
  SPEAKER_01: This was a sophisticated, automated system that completely blinded itself.
• 13:36
  SPEAKER_00: Yeah.
• 13:37
  SPEAKER_00: Zola manufactures the 731 series ventilators.
• 13:40
  SPEAKER_00: These are life-supporting devices.
• 13:42
  SPEAKER_00: They breathe for patients who literally cannot breathe for themselves.
• 13:45
  SPEAKER_00: High risk.
• 13:46
  SPEAKER_00: Extremely high risk.
• 13:48
  SPEAKER_00: Zola was having major compatibility issues where
• 13:50
  SPEAKER_00: the ventilators were completely shutting down in the field when placed too close
• 13:54
  SPEAKER_00: to MRI machines.
• 13:55
  SPEAKER_00: The strong magnetic fields were interfering with the internal electronics and valves.
• 13:59
  SPEAKER_00: This is a catastrophic failure that eventually led to a class, I recall.
• 14:03
  SPEAKER_01: But the recall was heavily delayed.
• 14:05
  SPEAKER_01: Why?
• 14:06
  SPEAKER_01: Because Zozo's statistical complaint-trending algorithm was fundamentally flawed.
• 14:10
  SPEAKER_01: Let's break down how this algorithm actually worked.
• 14:13
  SPEAKER_01: When a hospital reported that a ventilator shut down near an MRI,
• 14:16
  SPEAKER_01: Zozo would bring the device back.
• 14:17
  SPEAKER_01: A QA technician would test it on a bench in their lab.
• 14:20
  SPEAKER_01: But there is no giant magnetic field in the QA lab,
• 14:22
  SPEAKER_01: so of course the ventilator would work perfectly on the bench.
• 14:25
  SPEAKER_00: And because it worked on the bench, the technician would code the complaint as no fault found.
• 14:30
  SPEAKER_00: Sometimes they would code it user error,
• 14:32
  SPEAKER_00: or if the hospital didn't send the device back, they coded it, no product returned.
• 14:37
  SPEAKER_01: But the algorithm was programmed to only escalate confirmed hardware failures.
• 14:42
  SPEAKER_01: Every time a technician entered No Fault Found,
• 14:44
  SPEAKER_01: the algorithm stripped that complaint out of the danger queue.
• 14:47
  SPEAKER_00: Just made it disappear.
• 14:48
  SPEAKER_01: Right.
• 14:49
  SPEAKER_01: It essentially told the management team, hey, nothing to see here.
• 14:52
  SPEAKER_01: This statistical trend doesn't meet the escalation criteria.
• 14:55
  SPEAKER_00: It creates an illusion of control.
• 14:57
  SPEAKER_00: No Fault Found acts as a shield to avoid opening a cappy.
• 15:01
  SPEAKER_00: So the expectation is the same, but the lens is different.
• 15:29
  SPEAKER_00: Exactly.
• 15:30
  SPEAKER_00: The difference now is that the QMSR demands a very explicit systemic focus
• 15:35
  SPEAKER_00: on corrective action, preventing these issues from hiding in your data.
• 15:39
  SPEAKER_01: Let's look at one final comparison, rework.
• 15:42
  SPEAKER_01: Linemaster got hit under ISO clause 8.3.4 because an assembler didn't apply torque
• 15:47
  SPEAKER_01: to a laser foot pedal.
• 15:49
  SPEAKER_01: Let's contrast that with Longhorn vaccines and diagnostics from February 2026.
• 15:53
  SPEAKER_00: Sure.
• 15:53
  SPEAKER_00: Longhorn is a specification developer for the Prime Store MTM device.
• 15:58
  SPEAKER_00: This is a transport medium used for stabilizing
• 16:00
  SPEAKER_00: and transporting highly infectious samples,
• 16:02
  SPEAKER_00: specifically things like influenza and
• 16:04
  SPEAKER_01: tuberculosis.
• 16:06
  SPEAKER_00: And they were cited under the old QSR requirement for rework 21 CFR 820.90B2.
• 16:12
  SPEAKER_01: The stakes here are visceral.
• 16:14
  SPEAKER_01: We are talking about a tube designed to hold aerosolized tuberculosis
• 16:17
  SPEAKER_01: during transport in a van or, you know, testing in a diagnostic lab.
• 16:21
  SPEAKER_01: And the FDA found that Longhorn was reworking nonconforming devices that had,
• 16:24
  SPEAKER_01: quote, leaky caps, specks and floaters.
• 16:27
  SPEAKER_00: I mean, a leaky cap on a tuberculosis transport tube is a massive biological hazard.
• 16:32
  SPEAKER_01: Yeah, I'd say so.
• 16:33
  SPEAKER_00: But when Longhorn reworked these lots,
• 16:35
  SPEAKER_00: they did not conduct any retesting or reevaluation of the product after the rework.
• 16:40
  SPEAKER_00: They just tweet the caps and sent them out the door.
• 16:42
  SPEAKER_01: No testing at all.
• 16:43
  SPEAKER_00: None.
• 16:44
  SPEAKER_00: They made no determination of what adverse effects the rework might have had on
• 16:47
  SPEAKER_00: the structural integrity of the tube.
• 16:49
  SPEAKER_01: So what does this all mean?
• 16:51
  SPEAKER_01: The mechanics of the failure are identical to Linemaster.
• 16:54
  SPEAKER_00: Right.
• 16:54
  SPEAKER_00: The citation syntax has shifted directly to the ISO structure.
• 17:19
  SPEAKER_00: If you are a QA professional auditing your own rework procedures today,
• 17:23
  SPEAKER_00: you must map them to 8.3.4, not the old QSR subparts.
• 17:28
  SPEAKER_01: Which brings us to the most important part of this deep dive.
• 17:31
  SPEAKER_01: We've explored the psychological shift.
• 17:33
  SPEAKER_01: We've seen how the FDA hunts for blind spots in data rather than just engineering flaws.
• 17:39
  SPEAKER_01: How do you,
• 17:40
  SPEAKER_01: the senior QARA leader listening right now,
• 17:43
  SPEAKER_01: bulletproof your systems based on this intelligence?
• 17:46
  SPEAKER_01: What are the immediate actionable takeaways?
• 17:49
  SPEAKER_00: Well, number one, you must desilo your risk management immediately.
• 17:52
  SPEAKER_00: As we saw with Envoy and Linemaster,
• 17:54
  SPEAKER_00: you can no longer point an auditor to a static design hazard analysis.
• 17:58
  SPEAKER_01: Right.
• 17:58
  SPEAKER_01: It can't just be on a shelf.
• 18:00
  SPEAKER_00: Exactly.
• 18:00
  SPEAKER_00: Process FMEAs and production risk controls are strictly required on the floor
• 18:04
  SPEAKER_00: under QMSR Clause 7.1.
• 18:07
  SPEAKER_00: Risk must dictate how your operators work every single day.
• 18:11
  SPEAKER_01: Okay.
• 18:11
  SPEAKER_01: And number two,
• 18:12
  SPEAKER_01: you need to audit your KPA escalation and your complaint coding algorithms today,
• 18:16
  SPEAKER_01: like right now.
• 18:17
  SPEAKER_01: Look at the mechanics of your software.
• 18:19
  SPEAKER_01: Do not let no fault found or user error become a shield that prevents your system
• 18:23
  SPEAKER_01: from triggering an investigation like Zeal did with their ventilators.
• 18:27
  SPEAKER_01: And for the love of all things regulatory,
• 18:29
  SPEAKER_01: ensure your electronic systems absolutely prevent a root cause field
• 18:33
  SPEAKER_01: from being left blank on And number three,
• 18:35
  SPEAKER_01: update your terminology and map your processes.
• 18:38
  SPEAKER_01: Ensure that your legacy standard operating procedures map
• 18:40
  SPEAKER_00: explicitly to the ISO 135.
• 18:52
  SPEAKER_01: So if you have an environmental control issue.
• 18:54
  SPEAKER_00: If you have an environmental control issue impacting your manufacturing floor,
• 18:58
  SPEAKER_00: you need to be prepared to defend it under Clause 6.4.1 for Work Environment,
• 19:03
  SPEAKER_00: linking it directly to your equipment calibration.
• 19:06
  SPEAKER_00: We connect this to the bigger picture.
• 19:07
  SPEAKER_00: These warning letters are not just punishments for specific companies.
• 19:11
  SPEAKER_00: They are a roadmap published by the FDA.
• 19:13
  SPEAKER_00: They are showing you exactly how they are going to conduct your next audit.
• 19:17
  SPEAKER_01: The QSR era is officially over.
• 19:19
  SPEAKER_01: The Lionmester warning letter proves that the FDA isn't just paying lip service to
• 19:23
  SPEAKER_01: the QMSR transition.
• 19:24
  SPEAKER_01: They are on the ground,
• 19:25
  SPEAKER_01: actively enforcing the specific ISO clauses,
• 19:28
  SPEAKER_01: and they are looking at how your data systems either illuminate
• 19:31
  SPEAKER_01: or hide your failures.
• 19:33
  SPEAKER_00: They are enforcing the holistic view.
• 19:35
  SPEAKER_00: They're looking at how your room temperature affects your calibration torque,
• 19:39
  SPEAKER_00: how your software monitors that temperature,
• 19:41
  SPEAKER_00: and how your risk management oversees the entire interconnected process.
• 19:45
  SPEAKER_01: We want to thank you for spending your time with us on this deep dive into
• 19:48
  SPEAKER_01: the regulatory sources.
• 19:49
  SPEAKER_01: We know how demanding your role is and how high the stakes are for the patients
• 19:53
  SPEAKER_01: who rely on your devices.
• 19:54
  SPEAKER_01: We hope this intelligence helps you navigate the new QMSR landscape with confidence.
• 19:59
  SPEAKER_00: It is a complex transition,
• 20:01
  SPEAKER_00: but it is entirely manageable when you understand the mechanics of
• 20:03
  SPEAKER_00: the auditor's new lens.
• 20:05
  SPEAKER_01: I want to leave you with a final, lingering thought.
• 20:08
  SPEAKER_01: Linemaster got slapped with a historic first-of-its-kind warning letter because
• 20:12
  SPEAKER_01: an FDA auditor saw a literal blank space on a root cause form.
• 20:17
  SPEAKER_01: It makes you wonder.
• 20:18
  SPEAKER_01: If an FDA auditor walked into your facility tomorrow and pulled
• 20:21
  SPEAKER_01: a random statistical sample of your closed complaints from last Tuesday...
• 20:25
  SPEAKER_01: How many hidden NAs,
• 20:26
  SPEAKER_01: undocumented reworks,
• 20:27
  SPEAKER_01: or no-fault founds are lurking in your legacy quality records right now,
• 20:32
  SPEAKER_01: just waiting to trigger a brand new QMSR citation?